{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"67.3"},{"groupId":"OG001","value":"69.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"327"},{"groupId":"OG001","value":"322"}],"units":"Participants"}],"groups":[{"description":"Bevacizumab infusions were administered every two weeks at a dose of 10 mg/kg for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A was administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.","id":"OG000","title":"Bevacizumab + IFN-Alfa-2A"},{"description":"Placebo matched with Bevacizumab infusions were administered every two weeks for 52 weeks or until disease progression or unacceptable toxicity. IFN-Alfa-2A was administered 3 times per week as a subcutaneous injection at a dose of 9 MIU for 52 weeks or until disease progression or major toxicity.","id":"OG001","title":"Placebo + IFN-Alfa-2A"}],"paramType":"NUMBER","populationDescription":"ITT population included all participants randomized into the study.","reportingStatus":"POSTED","timeFrame":"Baseline up to 4.25 years","title":"Percentage of Participants Who Died","type":"PRIMARY","unitOfMeasure":"percentage of participants"}